iShares Silver Trust vs Twist Bioscience Corp — how do they compare? iShares Silver Trust trades at $59.11, while Twist Bioscience Corp trades at $124.13 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| SLV | TWST | |
|---|---|---|
52-Week High | $105.57 | $124.88 |
52-Week Low | $33.89 | $24.16 |
Market Cap | — | $7.72B |
Sector | — | Health |
Enterprise Value | — | $7.65B |
Signals from Pluang's Aura AI — not financial advice
SLV trades at $59.24, down 0.29% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, though prices eased ahead of CPI data. Financial ratios are unavailable as SLV is an ETF tracking physical silver, not a company with earnings.
The outlook for SLV hinges on silver's industrial and monetary demand, with support from AI infrastructure needs and potential Fed dovishness. Risks include dollar strength, inflation data surprises, and volatility from leveraged ETF comparisons. Investors gain pure silver exposure without mining operational risks.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Trailing returns across standard periods
Latest headlines on both assets
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →